Evommune’s EVO756 Phase 2b Trial: An Emerging Catalyst in Atopic Dermatitis
TipRanks (Sat, 25-Apr 12:30 PM ET)
Analysts Offer Insights on Healthcare Companies: Evommune, Inc. (EVMN) and Edwards Lifesciences (EW)
TipRanks (Fri, 24-Apr 8:01 AM ET)
Business Wire (Mon, 6-Apr 9:00 AM ET)
Business Wire (Thu, 5-Mar 4:01 PM ET)
Evommune Secures $125 Million Private Placement Backed by Leading Healthcare Funds
Market Chameleon (Fri, 13-Feb 6:54 AM ET)
Evommune Announces $125 Million Private Placement
Business Wire (Thu, 12-Feb 8:30 PM ET)
Market Chameleon (Tue, 10-Feb 5:28 AM ET)
Market Chameleon (Tue, 10-Feb 3:22 AM ET)
Business Wire (Tue, 10-Feb 7:30 AM ET)
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.
Evommune trades on the NYSE stock market under the symbol EVMN.
As of April 28, 2026, EVMN stock price was flat at $25.00 with 81,067 million shares trading.
EVMN has a beta of 0.83, meaning it tends to be less sensitive to market movements. EVMN has a correlation of 0.01 to the broad based SPY ETF.
EVMN has a market cap of $900.46 million. This is considered a Small Cap stock.
Last quarter Evommune reported $0 in Revenue and -$1.43 earnings per share. This fell short of revenue expectation by $-6 million and missed earnings estimates by -$.68.
The top ETF exchange traded funds that EVMN belongs to (by Net Assets): VTI, IWM, VXF, SCHA, VTWO.
EVMN support price is $23.72 and resistance is $26.28 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that EVMN shares will trade within this expected range on the day.